In a recent study published in the journal Nature Medicine, an international team of researchers evaluated the efficacy, safety, and tolerability of extended-release ketamine tablets (R-107) in adult ...
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
Please provide your email address to receive an email when new articles are posted on . “Ulcerative colitis is a chronic inflammatory disease of the colon that can significantly affect a patient’s ...
Attention Deficit Hyperactivity Disorder (ADHD) is a chronic neurodevelopmental disorder leading to impairments in learning and behaviour. ADHD affects approx. 3-5% of adults and 5-9% of children and ...
1 st and only once-daily combination containing the active ingredient of TOPROL-XL ® (metoprolol succinate) ER tablets plus low-dose hydrochlorothiazide, offers the dual efficacy of a beta blocker and ...
AHMEDABAD, India--(BUSINESS WIRE)--Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) announces the launch of ...
October 7, 2010 — The US Food and Drug Administration (FDA) has approved clonidine hydrochloride, 0.1-mg and 0.2-mg, extended-release tablets (Kapvay; Shionogi Inc ...
Granules India Ltd on Thursday said its arm Granules Pharmaceuticals, Inc has received tentative approval from the US health regulator for its generic amphetamine extended-release tablets indicated ...
Pfizer Inc. announced today that the U.S. Food and Drug Administration has approved XELJANZ ® XR extended-release 11 mg and 22 mg tablets for the once-daily treatment of adult patients with moderately ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results